News
PTC Therapeutics faces pivotal FDA decisions for approvals that could potentially transform their long-term revenues. Click ...
Tidmarsh will temporarily guide CBER’s regulatory activities while the FDA searches for a permanent department lead.
From the meme stock revival to Trump's Fed feud, Peter Hodson looks at some of the summer's more bizarre trends ...
Vinay Prasad, the top vaccine regulator and chief scientific officer at the Food and Drug Administration (FDA) and a critic ...
The former official, Vinay Prasad, had been on the job three months and had recently come under attack by conservative ...
Shipment of delandistrogene moxeparvovec, a gene therapy for Duchenne muscular dystrophy (DMD), will resume following a ...
15h
India Today on MSNWhat forced Vinay Prasad to exit top job at US FDA in just 3 months
Indian-origin scientist Vinay Prasad resigned as the FDA's vaccine and gene therapy chief in just three months after backlash ...
But this time, the unknown is hitting the industry in a different way from when Prasad was tapped to lead CBER less than ...
Gene Therapy Market Gene therapy market surges on breakthroughs in genome editing, rising chronic & genetic disease cases, regulatory appro ...
The immediate ebullient reaction to Vinay Prasad’s ouster is understandable, and may ultimately be the correct one, Adam ...
Donald Trump reportedly ignored calls from Health Secretary Robert F. Kennedy Jr. not to fire the top vaccine official at the ...
Detailed price information for Sarepta Therapeutics (SRPT-Q) from The Globe and Mail including charting and trades.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results